158 related articles for article (PubMed ID: 17426361)
1. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection.
Warger T; Rechtsteiner G; Schmid B; Osterloh P; Schild H; Radsak MP
Clin Rev Allergy Immunol; 2007 Feb; 32(1):57-66. PubMed ID: 17426361
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Lopez PA; Denny M; Hartmann AK; Alflen A; Probst HC; von Stebut E; Tenzer S; Schild H; Stassen M; Langguth P; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):252-259. PubMed ID: 28655469
[TBL] [Abstract][Full Text] [Related]
3. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.
Stein P; Weber M; Prüfer S; Schmid B; Schmitt E; Probst HC; Waisman A; Langguth P; Schild H; Radsak MP
PLoS One; 2011; 6(11):e27911. PubMed ID: 22114725
[TBL] [Abstract][Full Text] [Related]
5. Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice.
Bialojan A; Sohl J; Rausch J; Aranda Lopez P; Denny M; Langguth P; Hartmann AK; Yagita H; Probst HC; Schild H; Radsak MP
Eur J Immunol; 2019 Nov; 49(11):2083-2094. PubMed ID: 31393597
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of imiquimod-based transcutaneous immunization using a nano-dispersed emulsion gel formulation.
Stein P; Gogoll K; Tenzer S; Schild H; Stevanovic S; Langguth P; Radsak MP
PLoS One; 2014; 9(7):e102664. PubMed ID: 25025233
[TBL] [Abstract][Full Text] [Related]
7. UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin.
Stein P; Rechtsteiner G; Warger T; Bopp T; Fuhr T; Prüfer S; Probst HC; Stassen M; Langguth P; Schild H; Radsak MP
J Invest Dermatol; 2011 Jan; 131(1):211-9. PubMed ID: 20739947
[TBL] [Abstract][Full Text] [Related]
8. 9-Phenanthrol enhances the generation of an CD8
Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod.
Rechtsteiner G; Warger T; Osterloh P; Schild H; Radsak MP
J Immunol; 2005 Mar; 174(5):2476-80. PubMed ID: 15728450
[TBL] [Abstract][Full Text] [Related]
10. Transcutaneous immunization in mice: induction of T-helper and cytotoxic T lymphocyte responses and protection against human papillomavirus-induced tumors.
Dell K; Koesters R; Gissmann L
Int J Cancer; 2006 Jan; 118(2):364-72. PubMed ID: 16052529
[TBL] [Abstract][Full Text] [Related]
11. Optimized dithranol-imiquimod-based transcutaneous immunization enables tumor rejection.
Hartmann AK; Bartneck J; Pielenhofer J; Meiser SL; Arnold-Schild D; Klein M; Stassen M; Schild H; Muth S; Probst HC; Langguth P; Grabbe S; Radsak MP
Front Immunol; 2023; 14():1238861. PubMed ID: 37727790
[TBL] [Abstract][Full Text] [Related]
12. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
Lefrançois L; Altman JD; Williams K; Olson S
J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
[TBL] [Abstract][Full Text] [Related]
13. Solid nanoemulsion as antigen and immunopotentiator carrier for transcutaneous immunization.
Gogoll K; Stein P; Lee KD; Arnold P; Peters T; Schild H; Radsak M; Langguth P
Cell Immunol; 2016 Oct; 308():35-43. PubMed ID: 27318760
[TBL] [Abstract][Full Text] [Related]
14. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Broomfield SA; van der Most RG; Prosser AC; Mahendran S; Tovey MG; Smyth MJ; Robinson BW; Currie AJ
J Immunol; 2009 May; 182(9):5217-24. PubMed ID: 19380767
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
[TBL] [Abstract][Full Text] [Related]
16. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization.
Hosoi A; Takeda Y; Furuichi Y; Kurachi M; Kimura K; Maekawa R; Takatsu K; Kakimi K
Cancer Res; 2008 May; 68(10):3941-9. PubMed ID: 18483280
[TBL] [Abstract][Full Text] [Related]
17. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
18. Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.
Itoh T; Celis E
J Immunother; 2005; 28(5):430-7. PubMed ID: 16113599
[TBL] [Abstract][Full Text] [Related]
19. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
[TBL] [Abstract][Full Text] [Related]
20. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
